

TI	Angiotensin-I-converting enzyme inhibitory peptides from tryptic hydrolysates of bovine α 2-casein										
AU	Tauzin, Jerome; Micio, Laurent; Gaillard, Jean-Luc										
CS	Laboratoire des BioSciences de l'Aliment, Faculte des Sciences et Techniques, UC 885 INRA, Universite Henri Poincare Nancy 1, Vandoeuvre-le- S-Nancy, 54506, Fr.										
EPO	FEBS Letters (2002), 531(2), 369-374										
CODEN: EPXXDM	CODEN: FEBIAL, ISSN: 0144-5793										
PT	Elsevier Science B.V.										
TA	Angiotensin-I-converting enzyme (ACE) inhibitory activity of a tryptic digest of bovine α 2-casein (α S2-CN) was extensively investigated. Forty-three peptide peaks were isolated and tested. Seven casokinins (i.e. CN-derived ACE inhibitory peptides) were identified and their IC50 values were determined. Four peptides exhibited an IC50 value lower than 20 μ M. Peptides α S2-CN (F174-181) and α S2-CN (F174-179) had IC50 values of 4 μ M. Surprisingly, deletion of the C-terminal dipeptide of two of these casokinins did not significantly alter their inhibitory activity.										
E.A.	RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD										
AN	ALL CITATIONS AVAILABLE IN THE RE FORMAT										
CNT											
1	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE						
EP 1374885	A1	20040102	EP 2003-370025	20030524							
R	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	20040102	FR 2002-8036	20020627							
FR 2841473	A1	20040102									
FR 2841473	B1	20040107									
CA 2490282	AA	20040108	CA 2003-2490282	20030524							
WO 200402509	A2	20040108	WO 2003-FR1945	20030624							
WO 200402509	A3	20040115									
W	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DR, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, IN, IR, IS, JP, KE, KG, KP, KR, LA, LC, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, ZW	20040115									
RW	GH, GM, KB, LS, MW, SD, SL, SZ, TZ, UG, ZN, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, AU 200325691	20040119	AU 200325691	20030624							
BR	2003012214	A	20050412	BR 2003-12214	20030624						
JP	2005510851	T2	20051013	JP 2004-516859	20030624						
RAI	FR 2003-80316	A	20030627								
WO	2003-FR1945	W	20030624								
E.CNT	THE INVENTION DISCLOSES PEPTIDES DERIVED FROM CASEIN α S2 WITH ACE-1 INHIBITING ACTIVITY FOR THE PREVENTION AND TREATMENT OF HYPERTENSION. THE PEPTIDES MAY BE INCLUDED IN PHARMACEUTICAL COMPS. AND FOODSTUFFS.										
5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD										
E.CNT	ALL CITATIONS AVAILABLE IN THE RE FORMAT										
7	ANSWER 2 OF 3	HCAPLUS	COPYRIGHT 2006	ACS on STN							
N	2003-509734	HCAPLUS									
I	Bioactive peptides from tryptic hydrolysate of bovine α 2-casein										
I	Tauzin, Jerome; Micio, Laurent; Roth, Stephane; Spieser, Estelle; Molle, Daniel; Gaillard, Jean-Luc										
S	Laboratoire des BioSciences de l'Aliment, Faculte des Sciences, UA INRA 885, Vandoeuvre-les-Nancy 54500, Fr.										
O	Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept. 10-15, 2000 (2001) Meeting Date 2000-755-756.										
O	Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Publisher: Editions EDK, Paris, Fr.										
CODEN: 68EDWK	ISBN: 2-84254-048-4										
CONFERENCE											
T	Conference										
T	English										
B	English α S2-casein was subjected to tryptic hydrolysis. Generated peptides had angiotensin-I-converting enzyme inhibitory activity and μ and δ opioid receptor binding activities.										
E.CNT	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD									
ALL CITATIONS AVAILABLE IN THE RE FORMAT											
7	ANSWER 3 OF 3	HCAPLUS	COPYRIGHT 2006	ACS on STN							
N	2002-039314	HCAPLUS									
138:162404											
7	ANSWER 3 OF 3	HCAPLUS	COPYRIGHT 2006	ACS on STN							
N	2003-370025	HCAPLUS									
R	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT										
P	EP 1374885	A1	20040102	EP 2003-370025							
DT	Patent										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025							
DT	AT										
LA	French										
PAT	FNT 1										
PA	Ingridia, Fr.										
SO	Eur. Pat. Appi., 19 pp.										
PA	CODEN: EPXXDW										
PA	Patent No.	KIND	DATE	APPLICATION NO.	DATE						
PI	EP 1374885	A1	20040102	EP 2003-370025</							

IE, SI, LT, LV, FR, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
FR 2841473 A1 20040102 FR 2002-8036 20020627
FR 2841473 B1 20040517
CA 2490282 AA 20040108 CA 2003-2490282 20030624
WO 2004002509 A2 20040108 WO 2003-FR1945 20030624
WO 2004002509 A3 20040415
W: AE, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BZ, CA, CH, CN
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
CM, HR, HU, ID, IL, IN, IS, IP, IE, KG, KP, KR, KZ, LC, LK, LR, OM,
LS, LT, LU, LV, MA, MD, MG, MN, MW, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TU, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, TZ, UG, ZN, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GH, ML, MR, NE, SN, TD, TG
AU 2003255691 A1 20040119 AU 2003-255691 20030624
JP 200512214 A 20050412 BR 2003-12214 20030624
JP 20051013 T2 20050113 JP 2004-516859 20030624
WO 2003-FR1945 W 20030624
PRAI FR 2002-8036 A 20020627
RE: CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE IN THE RE FORMAT

AB The invention discloses peptides derived from casein α S2 with ACE-inhibiting activity for the prevention and treatment of hypertension. The peptides may be included in pharmaceutical compns. and foodstuffs.

RE: CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
DN 140-241
TI Biotropic peptides from trypic hydrolysate of bovine α S2-casein
AU Tazulin, Jerome; Miclo, Laurent; Rott, Stéphane; Battice, Molle,
Daniel; Gaillard, Jean-Luc
CS Laboratoire des Biosciences de l'Aliment, Faculté des Sciences, UR INRA
885, Vandoeuvre-les-Nancy, 54500, France
SO Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept 10-15, 2000 (2001), Meeting Date 2000, 755-756.
Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Publisher: Editions EIK, Paris, Fr.
Conference: 69EDMK; ISBN: 2-84254-048-4
DT English
LA AB Bovine α S2-casein was subjected to trypic hydrolysis. Generated peptides had angiotensin I-converting enzyme inhibitory activity and μ and δ opioid receptor binding activities.

RE: CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
DN 138-162004
TI Angiotensin-I-converting enzyme inhibitory peptides from tryptic hydrolysate of bovine α S2-casein
AU Tazulin, Jerome; Miclo, Laurent; Gaillard, Jean-Luc
CS Laboratoire des Biosciences de l'Aliment, Faculté des Sciences et Techniques, UC 885 INRA, Université Henri Poincaré Nancy 1, Vandoeuvre-le-Nancy, 54506, Fr.
SO FEBS Letters (2002), 531(2), 369-374
CODEN: FEBSL; ISSN: 0014-5793
PB Elsevier Science B.V.
DT English
LA AB Angiotensin-I-converting enzyme (ACE) inhibitory activity of a tryptic digest of bovine α S2-casein (α S2-CN) was extensively investigated. Forty-three peptide peaks were isolated and tested. Seven casokinins (i.e. CN-derived ACE inhibitory peptides) were identified and their IC50 values were determined. Four peptides exhibited an IC50 value lower than 20 μ M. Peptides α S2-CN (FI74-161) and α S2-CN (FI74-179) had IC50 values of 4 μ M. Surprisingly, deletion of the C-terminal dipeptide of two of these casokinins did not significantly alter their inhibitory activity.

RE: CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002-758248 HCAPLUS
DN 138: 9063
TI The development of electro-membrane filtration for the isolation of bioactive peptides: the effect of membrane selection and operating parameters on the transport rate
AU Bargeman, G.; Koops, G.-H.; Houwing, J.; Breebaart, I.; van der Horst, H.C.; Wessling, M.
CS NIZO Food Research, Ede, 6710 BA, Neth.
SO Desalination (2002), 149 (1-3), 369-374
CODEN: DSINAH; ISSN: 0011-9164
PB Elsevier Science B.V.
DT Journal
LA AB The ability to produce functional food ingredients from natural sources becomes increasingly attractive to the food industry. Antimicrobial (bioactive) ingredients, like peptides and proteins, can be isolated from hydrolyzates with membrane filtration and/or chromatog. Electro-membrane filtration (EMF) is an alternative for the isolation of these usually strongly charged components. It is believed to be more selective than membrane filtration and less costly than chromatog. The isolation of bioactive peptides from a hydrolysate of α S2-casein, a protein originating from milk, was studied as a model separation for the development of EMF. This separation can be used as an example application for the isolation of other charged components from complex feedstocks in several industries. After 4 h EMF the product consisted for 100% of proven or anticipated charged bioactive components. Diffusion and convection were negligible in relation to electrophoretic transport, since only charged components were recovered in the permeate product. The most important peptide (268 on total protein, starting from 7.5% in the feed) was α S2-casein (183-207), a very potent peptide against Gram pos. and Gram neg. microorganisms. The transport rate of α S2-casein (183-207) was reduced strongly when a polysulfone membrane with a mol. weight cut-off below 20 kDa was used. The amount of α S2-casein (183-207) transported increased practically linearly with the concentration and the applied P.d. The use of desalinated feed to further increase the elec. field strength in the feed compartment resulted in higher transport rates, but this increase was lower than expected probably due to the lower electrophoretic mobility. An average transport rate of 2.5 and 4 g/m².h at maximum was achieved during 4 h EMF using GROPP (25 kDa) and GR10P (100 kDa) membranes, resp.

RE: CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1992-1569689 HCAPLUS
DN 117: 1569689
TI HPLC analysis of commercial casein phosphopeptides (CPP)
AU Hirayama, Masao; Toyota, Kyoko; Yamaguchi, Goichi; Hidemasa;
Naito, Hiroshi
CS Bio Sci. Lab., Meiji Seika Kaisha, Ltd., Sakado, 350-02, Japan
SO Bioscience, Biotechnology, and Biochemistry (1992), 56(7), 1126-7
CODEN: BBBE; ISSN: 0916-8451
DT Journal

FILE 'REGISTRY' ENTERED AT 14:31:44 ON 08 AUG 2006

L1 1 S NNAINPSK/SQSP

L2 4 S NNAINPSK/SQSP

L3 1 S FPLPQY/SQSP

L4 65 S FPLPQY/SQSP

L5 1 S FPLPQY/SQSP

L6 30 S FPLPQY/SQSP

FILE 'HCAPLUS' ENTERED AT 14:34:35 ON 08 AUG 2006

L7 3 S L1

L8 6 S L2

L9 2 S L3

L10 66 S L4

L11 3 S L5

L12 16 S L6

=> 8 14 and casein

66 L4

60044 CASEIN

24638 CASEINS

66633 CASEIN

(CASEIN OR CASEINS)

L13 17 14 AND CASEIN

=> d 113 1-17 bib abs

L13 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 20051493719 HCAPLUS

DN 143 :10600

TI Peptide derivatization for enhancing protein identification by mass

spectrometry

IN Relley, James P.; Beardsley, Richard L.

PA Indiana University Research and Technology Corporation, USA

SO PCT Int. Appl. 153 pp.

CODEN: PIXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2005052563 A1 20050609 WO 2004-U338932

W: AE, AG, AL, AM, AT, AU, AZ, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, FI, GE, GH, GR, HR, ID, IN, IS, JP, KZ, LK, LK, LR, LS, LT, LU, MA, MD, MU, MR, MN, MW, MK, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GR, KE, LS, MW, MZ, NA, NT, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BB, BG, CH, CY, EE, ES, FL, FR, GB, GR, HU, IE, IS, IT, IU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BI, CF, CG, CI, CM, GR, GN, NE, SN, TD, TG P 20031120

PRAI US 2003-521643P

AB One aspect of the present invention is directed to a dual labeling

strategy that enhances the mass spectrometry analysis of peptides.

In one embodiment a de novo sequencing method is provided that utilizes both

guanidination of lysine residues in conjunction with amidination of the

N-termini of peptides to be analyzed by mass spectrometry. This approach

facilitates identification of N- and C-terminal fragment ions.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 20051493719 HCAPLUS

DN 143:1265786

TI Isolation and characterisation of antibacterial peptides derived from the f(164-207) region of bovine α S2-casein

AU McCann, K. B.; Shiell, B. J.; Michalski, W. P.; Lee, A.; Wan, J.;

AU Roginski, H.; Coventry, M. J.

CS Institute of Land and Food Resources, Gilbert Chandler College, The

CS University of Melbourne, Werribee, VIC 3030, Australia

SO International Dairy Journal (2005), 15(2), 133-143

CODEN: IDAJ6; ISSN: 0958-6946

PB Elsevier B.V.

DT Journal

LA English

AB A chymosin digest of sodium caseinate, which showed antibacterial activity

against *Listeria innocua*, was fractionated using reverse phase high

performance liquid chromatog, and the purified antibacterial peptides were

characterized by mass spectrometry. N-terminal amino acid sequencing and

comparison to peptide masses of theor. enzymic digests of milk proteins.

Five antibacterial peptides, Cr1, Cr3, Cr4, Cr5 and Cr7 corresponding to

amino acid residues 101-207, 180-207, 175-207, 164-207 and 172-207 of

bovine α S2-casein, resp., were isolated. The minimal

inhibitory concentration of peptides Cr1, Cr4 and Cr5 was determined against a

range of Gram-pos. and Gram-neg. bacteria and showed similar activities to those

of the bacteriocin peptide, nisin and the antibacterial peptide,

lactoferricin B against certain Gram-pos. bacteria. A partially purified

chymosin digest of sodium caseinate (CRMIX) was prepared and observed to be

heat stable for up to 15 min on exposure to 121°. Although CRMIX

showed bactericidal activity against *Salmonella typhimurium* in 0.1% (w/v)

peptone medium, no antibacterial activity was observed when tested in skim

milk at the same concentration

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004-5123 HCAPLUS

DN 140:71022

TI Casein α S2 peptides with angiotensin I-converting enzyme

(ACE)-inhibiting activity for the preparation of medicaments and

foodstuffs for the treatment of hypertension

IN Tauzin, Jerome; Micol, Laurent; LeFranc, Catherine; Boudier,

PA Jean-Francoise; Gaillard, Jean-Luc

SO Eur Pat. Appl., 19 pp.

CODEN: EPXDW

DT

LA French

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2004-U370025

PI 20040102

EP 2003-370025

20030524

FR 2002-8036

20020627

IN

FR

CA 2003-2490282

20030624

WO 2003-FR1945

20030624

WO 200402509

A3

20040415

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A2

20040108

WO 2003-FR1945

20030624

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A3

20040415

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A2

20040108

WO 2003-FR1945

20030624

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A3

20040415

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A2

20040108

WO 2003-FR1945

20030624

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A3

20040415

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A2

20040108

WO 2003-FR1945

20030624

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A3

20040415

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A2

20040108

WO 2003-FR1945

20030624

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A3

20040415

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A2

20040108

WO 2003-FR1945

20030624

FR 2641473

B1

20040102

FR 200402509

AA

20040108

CA 2003-2490282

20030624

WO 200402509

A3

20040415

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
 AU 2003255651 A1 20040119 AU 2003-255691 20030624
 BR 200312214 A 20050412 BR 2003-12214 20030624
 JP 2005330851 T2 20051013 JP 2004-516859 20030624
 PRAI FR 2002-8036 A 20020627
 WO 2003-FR1945 W 20030624

AB The invention discloses peptides derived from casein α s2 with ACE-inhibiting activity for the prevention and treatment of hypertension. The peptides may be included in pharmaceutical compns. and foodstuff.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002-1887281 HCAPLUS
 DN 138-105839

TI Electro-membrane filtration for the selective isolation of bioactive peptides from an α s2-casein hydrolysate
 AU Bargeman, Gerrald; Houwing, Joukje; Recio, Isidra; Koops, Geert-Henk; Van der Horst, Caroline
 CS NIZO Food Research, Ede, 6710 BA, Neth.
 SO Biotechnology and Bioengineering (2002), 80(6), 599-609
 CODEN: BIBIAU; ISSN: 0006-3522
 PB John Wiley & Sons, Inc.
 DT Journal
 LA English
 AB In this study, pos. charged peptides with antimicrobial activity were isolated from an α s2-casein hydrolysate using batch-wise electro-membrane filtration (EMF). α s2- Casein f(183-207), a peptide with strong antimicrobial activity, predominated in the isolated product and was enriched from 7.5% of the total protein components in the feed to 25% in the permeate product. With conventional membrane diafiltration using the same membrane (GROOPP), isolation of this and other charged bioactive peptides could not be achieved. The economics of EMF are mainly governed by the energy costs and the capital investment, which is affected by the flux of the desired peptide. A maximum average transport rate of α s2-casein f(183-207) during batch-wise EMF of 1.2 g/m² h was achieved. Results indicate that an increase in the hydrolysate (feed) concentration, the applied p.d. and the conductivity of the permeate and electrode solns., and a reduction in the conductivity of the feed result in a higher transport rate of α s2-casein f(183-207). This is in line with the expectation that the transport rate is improved when the concentration, the elec. field strength or the electrophoretic mobility is increased, provided that the electrophoretic transport predominates. The expected energy consumption of the EMF process per g of peptide transported was reduced by approx. 50% by applying a low overall p.d. and by processing desalinated hydrolysate. Considerable improvements in transport rate, energy efficiency, and process economics seem to be attainable by addnl. optimization of the process parameters and the EMF module design.

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

Techniques, UC 885 INRA, Universite Henri Poincare Nancy 1, Vandoeuvre-le-
 S-Nancy, 54006, Fr.
 SO FEBS Letters (2002), 531(2), 369-374
 CODEN: FEBLAD; ISSN: 0014-5793
 PB Elsevier Science B.V.
 DT Journal
 LA English
 AB Angiotensin-I-converting enzyme (ACE) inhibitory activity of a tryptic digest of bovine α s2-casein (α s2-CN) was extensively investigated. Forty-three peptide peaks were isolated and tested. Seven casokinins (i.e. CH -derived ACE inhibitory peptides) were identified and their IC50 values were determined. Four peptides exhibited an IC50 value lower than 20 μ M. Peptides α s2-CN (f174-181) and α s2-CN (f174-179) had IC50 values of 4 μ M. Surprisingly, deletion of the C-terminal dipeptide of two of these casokinins did not significantly alter their inhibitory activity.
 RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002-771931 HCAPLUS
 DN 138-121522

TI Identification of Sequential IgE-Binding Epitopes on Bovine α s2-Casein in Cow's Milk Allergic Patients
 AU Busse, Paula J.; Jervinen, Kirsti-Marjut; Vila, Leticia; Beyer, Kirsten;
 Sampson, Hugh A.; Jaffee Institute for Food Allergy, Division of Allergy and Immunology, Department of Pediatrics, The Mount Sinai School of Medicine, New York, NY, 10029-6574, USA
 SO International Archives of Allergy and Immunology (2002), 129(1), 93-96
 CODEN: IAAIEC; ISSN: 1018-2438
 PB S. Karger AG
 DT Journal
 LA English
 AB Caseins are the major allergens responsible for cow's milk allergy (CMA). The authors have previously identified the IgE-binding epitopes of the major cow's milk (CM) proteins except for α s2-casein. Methods: Overlapping decapentapeptides representing the entire length of α s2-casein were synthesized on a cellulose-derivatized membrane. Sera from 13 CM-allergic children, 4-15 yr of age, with a median level of CM-specific IgE >100 kU/l (range 33.7 to >100 kU/l) were used to identify IgE-binding epitopes. Results: Four major and six minor sequential IgE-binding regions were identified on α s2-casein. The first major region is located in the middle of the protein at amino acids (AA) 83-100, and the other three major regions are located in the carboxy terminal portion of the protein at AA 143-158, 157-172 and 165-188. The minor IgE-binding regions were identified at AA 31-44, 43-56, 93-106, 105-114, 117-128, and 191-200. Conclusion: the authors identified 10 sequential IgE-binding regions on α s2-casein, and performed the first crucial step in the development of immunotherapeutic interventions for CMA.
 RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002-758248 HCAPLUS
 DN 138-0063

TI The development of electro-membrane filtration for the isolation of biactive peptides: the effect of membrane selection and operating parameters on the transport rate
 AU Bargeman, G.; Koops, G.-H.; Houwing, J.; Breebaart, I.; van der Horst, H. C.; Wessling, M.
 SO NIZO Food Research, Ede, 6710 BA, Neth.
 CS Desalination (2002), 149(1-3), 369-374

CODEN: DSNNAH; ISSN: 0011-9164
 PB Elsevier Science B.V.
 DT Journal
 LA English
 AB The ability to produce functional food ingredients from natural sources becomes increasingly attractive to the food industry. Antimicrobial (biactive) ingredients, like peptides and proteins, can be isolated from hydrolyzates with membrane filtration and/or chromatography. Electro-membrane filtration (EMF) is an alternative for the isolation of these usually strongly charged components. It is believed to be more selective than membrane filtration and less costly than chromatography. The isolation of biactive peptides from a hydrolyzate of α s2-casein, a protein originating from milk, was studied as a model separation for the development of EMF. This separation can be used as an example application for the isolation of other charged components from complex feedstocks in several industries. After 4 h EMF the product consisted for 100% of proven or anticipated charged bioactive components. Diffusion and convection were negligible in relation to electrophoretic transport, since only charged components were recovered in the permeate product. The most important peptide (26% on total protein, starting from 7.5% in the feed) was α s2-casein (183-207), a very potent peptide against Gram pos. and Gram neg. microorganisms. The transport rate of α s2-casein (183-207) was reduced strongly when polysulfone membrane with a mol. weight cut-off below 20 kDa was used. The amount of α s2-casein (183-207) transported increased practically linearly with the concentration and the applied P.D. The use of desalinated feeds to further increase the elec. field strength in the feed compartment resulted in higher transport rates, but this increase was lower than expected probably due to the lower electrophoretic mobility. An average transport rate of 2.5 and 4.9/m2.h at maximum was achieved during 4 h EMF using GR4PP (25 kDa) and GR4PP (100 kDa) membranes, resp.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE IN THE RE FORMAT
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2006 ACS ON STN
 AN 20027101628 HCAPLUS
 TI B-cell epitopes as a screening instrument for persistent cow's milk allergy
 AU Järvinen, Kirsi-Marjut; Beyer, Kirsten; Vila, Leticia; Chatchatee,
 Pantipa; Busse, Paula J.; Sampson, Hugh A.
 CS Division of Pediatric Allergy and Immunology and the Jaffe Institute for
 Food Allergy, The Mount Sinai School of Medicine, New York, NY, USA
 SO Journal of Allergy and Clinical Immunology (2002), 110(2), 293-297
 PB Mosby, Inc.
 DT Journal
 LA English
 AB The authors sought to assess whether recognition of IgE antibodies of certain epitopes of cow's milk proteins would clearly separate the patients with life-long cow's milk allergy (CMA) from those who will become clinically tolerant to cow's milk. According to the known IgE-binding regions of cow's milk proteins, 25 decapeptides of α 1-casein, α s2-casein, α -lactalbumin, and β -lactoglobulin, comprising the core epitopes, were synthesized on a cellulose-derivatized membrane. Sera from 10 patients with persistent CMA and 10 patients who subsequently outgrew their milk allergy were used to investigate the differences in epitope recognition. Five IgE-binding epitopes (2 on α 1-casein, 1 on α s2-casein, and 2 on β -lactoglobulin) were isolated from a peptide hydrolysate of bovine α s2-casein. The digested α s2-casein was fractionated by cation-exchange chromatography, after which the peptides in the two active fractions obtained were separated by high-performance liquid chromatography and sequenced by electrospray-

CASEIN, and AA 155-164 on ν kappa.-casein) identified all patients with persistent CMA. The presence of IgE antibodies to distinct allergenic epitopes of cow's milk proteins can be used as a marker of persistent CMA. Prospective studies are needed to investigate the usefulness of these informative epitopes in predicting life-long CMA in young children.

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2006 ACS ON STN
 AN 200237476 HCAPLUS
 DN 136:444141
 TI Three oligopeptide-binding proteins are involved in the oligopeptide transport of *Streptococcus thermophilus*
 AU Garault, Peggy; Le Bars, Dominique; Besset, Colette; Monnet, Véronique
 CS Unité de Biochimie et Structure des Protéines, Institut National de la Recherche Agronomique, Jouy en Josas, 78352, Fr.
 SO Journal of Biological Chemistry (2002), 277(1), 32-39
 CODEN: JBCRA3; ISSN: 0021-9258
 PB American Society for Biochemistry and Molecular Biology
 DT English
 AB The functions necessary for bacterial growth strongly depend on the features of the bacteria and the components of the growth media. Our objective was to identify the functions essential to the optimum growth of *Streptococcus thermophilus* in milk. Using random insertional mutagenesis on a *S. thermophilus* strain chosen for its ability to grow rapidly in milk, we obtained several mutants incapable of rapid growth in milk. We isolated and characterized one of these mutants in which an amid gene encoding an oligopeptide-binding protein (OBP) was interrupted. This gene was a part of an operon containing all the components of an ATP binding cassette transporter. Three highly homologous amidA genes encoding OBPs work with the same components of the ATP transport system. Their simultaneous inactivation led to a drastic diminution in the growth rate in milk and the absence of growth in chemical defined medium containing peptides as the nitrogen source. We constructed single and multiple neg. mutants for AmidA and cell wall proteinase (PrS), the only proteinase capable of hydrolyzing casein oligopeptides outside the cell. Growth experiments in chemical defined medium containing peptides indicated that AmidA1, AmidA2, and AmidA3 exhibited overlapping substrate specificities, and that the whole system allows the transport of peptides containing from 3 to 23 residues.
 RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2006 ACS ON STN
 AN 1999160093 HCAPLUS
 TI Identification of two distinct antibacterial domains within the sequence of bovine α s2-casein
 AU Recio, Isidra; Visser, Servaas
 CS Department of Product Technology, Section of Structure and Functionality, NIZO Food Research, Ede, 6710 BA, Neth.
 SO Biochimica et Biophysica Acta, General Subjects (1999), 1428(2-3), 314-326
 CODEN: BBGS3; ISSN: 0304-4165
 PB Elsvier B.V.
 DT Journal
 LA English
 AB Two distinct domains with antibacterial activity were isolated from a peptide hydrolysate of bovine α s2-casein. The digested α s2-casein was fractionated by cation-exchange chromatography, after which the peptides in the two active fractions obtained were separated by high-performance liquid chromatography and sequenced by electrospray-

ionization tandem mass spectrometry. The major component in each active fraction, f(183-207) and f(164-179), was further purified and the antibacterial activity of these components was tested against several microorganisms. Depending on the target bacterial strain, these peptides exhibited min. inhibitory concns. between 8 and 99 μ M. Peptide f(183-207) exhibited a consistently higher antibacterial activity than f(164-179), although both peptides showed a comparable hemolytic effect. A method of in situ enzymic hydrolysis on a cation exchange membrane to obtain a fraction enriched in the most active antibacterial domain is presented. The antibacterial and hemolytic activities are discussed in relation to the structure and hydrophobicity of the peptides.

RE. CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996453227 HCAPLUS
 DN 125123676
 TI Purification of antibacterial peptides from bovine milk
 IN Zucht, Hans-Dieter; Forssmann, Wolf-Georg; Raida, Manfred; Knut
 PA Germany
 SO Ger. Offen., 17 pp.
 CODEN: GMXXBX
 DT Patent
 LA German
 FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 4444753	A1	19960620	DE 1994-4444753	19941215
DE 9735877	C2	19980806		
WO 971002	WO 1996-EP1296			
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MN, MK, MW, PL, RO, SG, SI, SK, TR, TT, UR, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	A1	19971002	19960325	
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, MR, NE, SN, TD, TG	AU	19971017	19965-53342	19960325
EP 889902	A1	19990113	EP 1996-910013	19960325
JP 20000507941	B1	20010620		
JP 20000627	T2	20010715	JP 1997-533956	19960325
ES 2159021	E	20010916	AT 1996-910013	19960325
US 2002025928	T3	20010916	ES 1996-910013	19960325
US 6579649	A1	20020228	US 1998-115203	19980924
PRAI DE 1994-4444753	B2	19941215		
WO 1996-EP1296	W	19960325		
AB Fragments of α s2-casein, designated as casebiotics, are present in large amts. in bovine milk and show antibacterial activity against Escherichia coli. Thus, milk was subjected to cation-exchange chromatog. and 3 cycles of HPLC to isolate α s2-casein (165-203). The structure and biol. activity of this peptide were confirmed by synthesis. A related peptide, α s2-casein (166-203), was also prepared and showed similar biol. activity.				

L13 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 19951957680 HCAPLUS
 DN 12413426
 TI Calmodulin-binding peptides isolated from α -casein peptone
 IN Kizawa, Kenji; Naganuma, Keiko; Murakami, Umeji
 PA Biochem. Lab.; Kanebo Ltd.; Odawara, 250, Japan
 SO Journal of Dairy Research (1995), 62(4), 587-592
 CODEN: JDRSAN; ISSN: 0022-0299

PB Cambridge University Press
 DT English
 LA English
 AB Peptides that inhibit calmodulin-dependent cyclic nucleotide phosphodiesterase were isolated from a pepsin digest of α -casein. Anal. of these peptides showed that they corresponded to the α s2-casein sequences 164-179 (Leu-Lys-Lys-Ile-Ser-Gln-Arg-Tyr-Gln-Lys-Ala-Met-Lys-Pro-Trp-Ile-Gln-Pro-Gln-Tyr-Gln-His-Gln-Lys-Ala-Met-Lys-Pro-Trp-Ile-Gln-Pro-Lys-Thr-Lys-Gln-Lys-Ile-Pro-Tyr-Val-Arg-Tyr) and 183-207 (C-terminus, Val-Tyr-Gln-His-Gln-Lys-Ala-Met-Lys-Pro-Trp-Ile-Gln-Pro-Lys-Thr-Lys-Gln-Lys-Ile-Pro-Tyr-Val-Arg-Tyr-Leu). These peptides inhibited calmodulin-induced cyclic nucleotide phosphodiesterase activity over the range 1-50 μ M without affecting the basal enzyme activity. These results demonstrated that the affinities of certain peptides for calmodulin are comparable to the affinities of certain endogenous neuropeptides and proteins that interact with calmodulin.

L13 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 19951942173 HCAPLUS
 DN 123133116
 TI Caseocidin-1: a casein- α s2 derived peptide exhibits antibacterial activity
 AU Zucht, Hans-Dieter; Raida, Manfred; Adermann, Knut; Maegert, Hans-Juergen; Forssmann, Wolf-Georg
 CS Niedersaechsisches Institut fuer Peptid-Forschung (IPF), Peodor-Lyenne-Straeze 31, Hannover, D-30625, Germany
 DT Journals
 SO FEBS Letters (1995), 372(2,3), 185-188
 CODEN: FEBLAU; ISSN: 0014-5793
 PB Elsevier
 LA English
 AB Here we report the isolation and characterization of an antibacterial peptide from bovine milk inhibiting the growth of Escherichia coli and Staphylococcus carnosus. The primary structure of the peptide was revealed as a 39-amino-acid-containing fragment of bovine α s2-casein (position 165-203) by means of Edman amino acid sequencing and mass spectrometry. Since human milk does not contain any casein- α s2, these findings could explain the different influence of human and bovine milk on the gastrointestinal flora of the bucking.
 L13 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 1992150149 HCAPLUS
 DN 116150149
 TI Platelet aggregation-inhibiting hexadecapeptide from pepsin hydrolyzates of casein
 IN Kizawa, Kenji; Naganuma, Keiko; Murakami, Umeji; Takemoto, Taira
 PA Kanebo, Ltd., Japan
 SO Jpn. Kokai Tokyo Koho, 7 pp.
 CODEN: JICKAF
 DT Patent
 LA Japanese
 FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 0255094	A2	19911113	JP 1990-52553	19900302
AB H-Leu-Lys-Ile-Ser-Gln-Arg-Tyr-Gln-Lys-Phe-Ala-Leu-Pro-Gln-Tyr-OH (I) or its salts are isolated from pepsin hydrolyzates of α -casein. I inhibits blood platelet aggregation and is useful for treatment and prevention of thrombosis. α -Casein (10 g) in aqueous HCl was treated with pepsin at 37° for 1 h and applied to column chromatog. to give 35.0 mg I. trifluoroacetate salt. I trifluoroacetate salt inhibited ADP-induced aggregation of platelet-rich				

plasma with IC50 of 3358 μ M.

L13 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1989-611264 HCAPLUS

DN 111:11264 HCAPLUS

TI Application of reversed-phase high-performance liquid chromatography to the separation of peptides from phosphorylated and dephosphorylated casein hydrolysates

AU Lemieux, Line; Amiot, Jean

SO Dep. Sci. Technol. Aliments, STELA, Sainte-Foy, QC, G1K 7P4, Can.

CODEN: JOCRAM; ISSN: 0021-9673

DT Journal

LA English

AB Peptides from phosphorylated and dephosphorylated casein hydrolysates were fractionated on a TSK G2000SW size-exclusion column. The fractionated peptides were separated by reversed-phase HPLC on a C18 column using aqueous trifluoroacetic acid as the mobile phase and acetonitrile as the mobile phase modifier in the linear gradient elution system. The separation of the dephosphorylated and phosphorylated hydrolysates gave 213 and 187 peptides, resp., of which 116 and 99, resp., were reported. A study of their composition and retention times verified that the peptide separation mechanism includes ionic interactions, H bonding and peptide characteristics, in addition to overall peptide hydrophobicity.

L13 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1977-417534 HCAPLUS

DN 87:17534 HCAPLUS

TI Complete amino acid sequence of bovine α S2-casein
AU Brignon, Chantaline; Ribadeau Dumas, Bruno; Mercier, Jean Claude;
Pellissier, Jean Pierre; Das, B. C.
CS Lab. Rech. Protéines, Inst. Natl. Rech. Agron., Jouy-en-Josas, Fr.
SO FEBS Letters (1977), 76(2), 274-9
CODEN: FEBIAL; ISSN: 0014-5793

DT Journal

LA English
AB The complete primary amino acid sequence of bovine α S2-casein was determined by standard methods. In addition, the possible sites of phosphorylation on this protein were localized. This protein contains 207 amino acid residues, including 2 cysteines, and 10-13 phosphate groups and has a calculated mol. weight of 25,150-15,390 daltons.

L13 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1970-519353 HCAPLUS

DN 73:119353 HCAPLUS

TI Isolation of bitter peptides from tryptic hydrolyzate of casein and their chemical structure
AU Matoba, Teruyoshi; Hayashi, Rikimaru; Hata, Tadao
CS Res. Inst. Food Sci., Kyoto Univ., Kyoto, Japan

SO Agricultural and Biological Chemistry (1970), 34(8), 1235-43
CODEN: ABCHA6; ISSN: 0002-1369
DT Journal

LA English

AB Three bitter peptides were isolated from the tryptic hydrolyzate of casein by extraction with BuOH, precipitation at pH 5.4, gel filtration with Sephadex G-15, chromatog. on Dowex 50, and paper chromatog. The primary structures of the peptides were: Gly-Pro-Phe-Pro-Val-Ileu, Phe-Phe-Val-Ala-Pro-Phe-Pro-Glu-Val-Phe-Gly-Lys, and Phe-Ala-Leu-Pro-Gly-Tyr-Leu-Lys.

=> d his

(FILE 'HOME' ENTERED AT 14:31:21 ON 08 AUG 2006)

FILE 'REGISTRY' ENTERED AT 14:31:44 ON 08 AUG 2006

L1 1 S NMAINFSK/SQSP

L2 4 S NMAINFSK/SQSP

L3 1 S FALPQV/SQSP

L4 65 S FALPQV/SQSP

L5 1 S FPOQY/SQSP

L6 30 S FPOQY/SQSP

FILE 'HCAPLUS' ENTERED AT 14:34:35 ON 08 AUG 2006

L7 3 S L1

L8 6 S L2

L9 2 S L3

L10 66 S L4

L11 3 S L5

L12 16 S L6

L13 17 S L4 AND CASEIN

=> s 16 and casein

L14 16 L6

60044 CASEIN

24638 CASEINS

66633 CASEIN

(CASEIN OR CASEINS)

L14 16 L6 AND CASEIN

=> d 114 1-6 bib abs

L14 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2005-573884 HCAPLUS

DN 143:282366 HCAPLUS

TI The specificity of oligopeptide transport by *Streptococcus thermophilus* resembles that of *Lactococcus lactis* and not that of pathogenic streptococci
AU Juille, Odile; Le Bars, Dominique; Juillard, Vincent
CS Unité de Biochimie et Structure des Protéines, Institut National de la Recherche Agronomique, Centre de Recherches de Jouy-en-Josas, Jouy-en-Josas, 78352, Fr.
SO Microbiology (Reading, United Kingdom) (2005), 151 (6), 1987-1994
CODEN: MRB20; ISSN: 1350-0872
PB Society for General Microbiology
DT Journal
LA English
AB Peptide transport is a crucial step in the growth of *S. thermophilus* in protein- or peptide-containing media. The objective of the present work was to determine the specificity of peptide transport by this widely used lactic acid bacterium. To reach that goal, complementary approaches were employed. The capability of a proteinase-negative *S. thermophilus* strain to grow in a chemically defined medium containing a mixture of peptides isolated from milk as the source of amino acids was analyzed. Peptides were separated into 3 size classes by ultrafiltration. The strain was able to use peptides up to 3.5 kDa during growth, as revealed by liquid chromatog. and mass spectrometry analyses. The same strain was grown in chemical defined medium containing a tryptic digest of casein, and the resp. time-course consumption of the peptides during growth was estimated. The ability to consume large peptides (523 residues) was confirmed, as long as they are cationic and hydrophobic. These results were confirmed by peptide transport studies. Extension of the study to 11 other strains revealed that they all shared these preferences.

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN

AN	200415123	HCAPLUS	RE.CNT 4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
DN	140,71022			ALL CITATIONS AVAILABLE IN THE RE FORMAT
TI	Casein α S2 peptides with angiotensin I-converting enzyme (ACE)-inhibiting activity for the preparation of medicaments and foodstuffs for the treatment of hypertension		L14	ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN
IN	Tauzin, Jerome; Miclo, Laurent; Leiranc, Catherine; Boudier, Jean-Francois; Gaillard, Jean-Luc		AN	2002-839514 HCAPLUS
PA	Ingridia, Fr.		DN	138:162404
SO	Eur. Pat. Appl. , 19 pp.		TI	Angiotensin-I-converting enzyme inhibitory peptides from tryptic hydrolysate of bovine α S2- casein
DT	Patent		AU	Tauzin, Jerome; Miclo, Laurent; Gaillard, Jean-Luc
LA	French		CS	Laboratoire des BioSciences de l'Aliment, Faculte des Sciences et Techniques, UC 885 INRA, Universite Henri Poincare Nancy 1, Vandoeuvre-le- s-Nancy, 54506, Fr.
FAN.CNT 1	PATENT NO.	KIND	DATE	APPLICATION NO.
PI	EP 1374885	A1	20040102	EP 2003-370025
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, BG, CZ, EE, HU, SK			20030624
	FR 2841473	A1	20040102	FR 2002-8036
	FR 2841473	B1	20040102	20030624
	CA 2490382	AA	20040108	CA 2003-2490282
	WO 2004002509	A2	20040108	WO 2003-FR1945
	W: AE, AG, AL, AN, AT, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZN, ZW			20030624
	RW: GH, GM, KE, LS, MM, MZ, SD, SL, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, BE, ES, FI, FR, GB, GR, HU, IL, LU, MC, NL, PT, RO, SB, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GR, ML, MR, NE, TD, TG			20030624
	AU 200355691	A1	20040119	AU 2003-255691
	BR 2003012214	A	20050412	BR 2003-12214
	JP 2005530851	T2	20050103	JP 2004-516859
	PRAI FR 2002-8036	A	20020627	20030624
	WO 2003-FR1945	W	20030624	
	AB			The invention discloses peptides derived from casein α S2 with ACE-inhibiting activity for the prevention and treatment of hypertension. The peptides may be included in pharmaceutical compns. and foodstuffs.
RE.CNT 5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD			ALL CITATIONS AVAILABLE IN THE RE FORMAT
L14	ANSWER 3 OF 16 HCAPLUS	COPYRIGHT 2006 ACS on STN		
AN	2003150734	HCAPLUS		
DN	140,241			
TI	Bioactive peptides from tryptic hydrolysate of bovine α S2- casein			
AU	Tauzin, Jerome; Miclo, Laurent; Roth, Stephane; Spiesser, Etelle; Molle, Daniel; Gaillard, Jean-Luc; Faculte des Sciences, UA INRA 885, Vandoeuvre-les-Nancy, 54500, Fr.			
CS	Laboratoire des BioSciences de l'Aliment, Faculte des Sciences, UA INRA 885, Vandoeuvre-les-Nancy, 54500, Fr.			
SO	Pepides 2000. Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept. 10-15, 2000 (2001). Meeting Date 2000, 755-756. Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Publisher: Editions EDK, Paris, Fr.			
DT	Conference			CONFERENCE: 2-84254-048-4
LA	English			
AB	Bovine α S2- casein was subjected to tryptic hydrolysis. Generated peptides had angiotensin I-converting enzyme inhibitory activity and μ and δ opioid receptor binding activities.			
RE.CNT 9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD			ALL CITATIONS AVAILABLE IN THE RE FORMAT
L14	ANSWER 5 OF 16 HCAPLUS	COPYRIGHT 2006 ACS on STN		
AN	2002-771931	HCAPLUS		
DT	Journal			
LA	English			
AB	Background: Caseins are the major allergens responsible for cow's milk allergy (CMA). The authors have previously identified the IgE-binding epitopes on Bovine α S2- casein in Cow's Milk Allergic Patients. Methods: Overlapping decapeptides representing the entire length of α S2- casein were synthesized on a cellulose-derivatized membrane. Sera from 13 CM-allergic children, 4-15 yr of age, with a median level of IgE >100 kU/l (range 33.7 to >100 kU/l) were used to identify IgE-binding epitopes. Results: Four major and six minor sequential IgE-binding regions were identified on α S2- casein. The first major region is located in the middle of the protein at amino acids (AA) 83-100, and the other three major regions are located in the carboxy terminal portion of the protein at AA 143-158, 157-172 and 165-188. The minor IgE-binding regions were identified at AA 31-44, 43-56, 93-106, 105-114, 117-128, and 191-200. Conclusion: the authors identified 10 sequential IgE-binding regions on α S2- casein and performed the first crucial step in the development of immunotherapeutic interventions for CMA.			

L14 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002-75248 HCAPLUS
 DN 138-90063
 TI The development of electro-membrane filtration for the isolation of bioactive peptides: the effect of membrane selection and operating parameters on the transport rate
 AU Bargeman, G.; Hoops, G.-H.; Houwing, J.; Breebaart, I.; van der Horst, H. C.; Wesseling, M.
 CS NIZO Food Research, Ede, 6710 BA, Neth.
 SO Desalination (2002), 149 (1/3), 369-374
 CODEN: DSNWAH; ISSN: 0011-9164
 PB Elsevier Science B.V.
 DT Journal
 LA English
 AB The ability to produce functional food ingredients from natural sources becomes increasingly attractive to the food industry. Antimicrobial (biactive) ingredients, like peptides and proteins, can be isolated from hydrolyzates with membrane filtration and/or chromatog. Electro-membrane filtration (EMF) is an alternative for the isolation of these usually strongly charged components. It is believed to be more selective than membrane filtration and less costly than chromatog. The isolation of biactive peptides from a hydrolyzate of α s2-casein, a protein originating from milk, was studied as a model separation for the isolation of other charged components from complex feedstocks in several industries. After 4 h EMF the product consisted for 100% of proven or anticipated charged biactive components. Diffusion and convection were negligible in relation to electrophoretic transport, since only charged components were recovered in the permeate product. The most important peptide (26% on total protein, starting from 7.5% in the feed) was α s2-casein (183-207), a very potent peptide against Gram pos. and Gram neg. microorganisms. The transport rate of α s2-casein (183-207) was reduced strongly when a polysulfone membrane with a mol. weight cut-off below 20 kDa was used. The amount of α s2-casein (183-207) transported increased practically linearly with the concentration and the applied p.d. The use of desalinated feeds to further increase the elec. field strength in the feed compartment resulted in higher transport rates, but this increase was lower than expected, probably due to the lower electrophoretic mobility. An average transport rate of 2.5 and 4 g/m².h atc max was achieved during 4 h EMF using GR60PP (25 kDa) and GR41PP (100 kDa) membranes, resp.
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

> d 114 1-16 bib abs

L14 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005-157884 HCAPLUS
 DN 143-1282366
 TI The specificity of oligopeptide transport by *Streptococcus thermophilus* resembles that of *Lactococcus lactis* and not that of pathogenic streptococci.
 AU Juille, Odile; Le Bars, Dominique; Juillard, Vincent
 CS Unite de Biochimie et Structure des Proteines, Institut National de la Recherche Agronomique, Centre de Recherches de Jouy-en-Josas, Jouy-en-Josas, 78352, Fr.
 SO Microbiology (Reading, United Kingdom) (2005), 151 (6), 1987-1994
 CODEN: MROBEO; ISSN: 1350-0872
 PB Society for General Microbiology
 DT Journal
 LA English
 AB Peptide transport is a crucial step in the growth of *S. thermophilus* in protein- or peptide-containing media. The objective of the present work was to determine the specificity of peptide utilization by this widely used lactic acid bacterium. To reach that goal complementary approaches were employed. The capability of a proteinase-neg. *S. thermophilus* strain to grow in a chemical defined medium containing a mixture of peptides isolated from milk as the source of amino acids was analyzed. Peptides were separated into 3 size classes by ultrafiltration. The strain was able to use peptides up to 3.5 kDa during growth, as revealed by liquid chromatog. and mass spectrometry analyses. The same strain was grown in chemical defined medium containing a tryptic digest of casein and the resp. time-course consumption of the peptides during growth was estimated. The ability to consume large peptides (\geq 3 residues) was confirmed, as long as they are cationic and hydrophobic. These results were confirmed by peptide transport studies. Extension of the study to 11 other strains revealed that they all shared these preferences.
 RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004-15123 HCAPLUS
 DN 140-71022
 TI Casein α s2 peptides with angiotensin I-converting enzyme (ACE)-inhibiting activity for the preparation of medicaments and foodstuffs for the treatment of hypertension
 IN Tazuin, Jerome; Lefanc, Catherine; Boudier, Jean-Francois; Gaillard, Jean-Luc
 PA Ingredia, Fr.
 SO Eur. Pat. Appl., 19 pp.
 CODEN: EPXXDW
 DT Patent
 LA French
 FAN: CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI EP 1374885 A1 20040102 EP 2003-370025
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SB, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, BE, HU, SK
 FR 2841473 A1 20040102 FR 2002-8036 20020627
 FR 2841473 B1 20040917
 CA 2490282 A2 20040108 CA 2003-2490282 20030524
 WO 2004002509 A2 20040108 WO 2003-FR1945 20030524
 WO 2004002509 A3 20040415
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CZ, CH, CN, CO, CR, CU, CZ, DE, DK, DM, D2, EC, EE, FI, GB, GD, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, MG, MN, MW, MX, MZ, NI, NO, NZ, OM, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, TJ, TM, TR, TT, T2, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, JP, KE, KG, KP, KR, SI, SK, TR, AU 2003255631 A1 20040119 AU 2003-255691 20030524
 BR 2003012214 A 20050412 BR 2003-12214 20030524
 JP 2005530851 T2 20051013 JP 2004-516659 20030624
 PRAI FR 2002-8036 A 20020627
 WO 2003-FR1945 W 20030524
 AB The invention discloses peptides derived from casein α s2 with ACE-inhibiting activity for the prevention and treatment of hypertension. The peptides may be included in pharmaceutical compns. and foodstuffs.
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN
 DN 2002:1509734 HCAPLUS
 TI Bioactive peptides from tryptic hydrolysate of bovine α S2-casein
 AU Tazin, Jerome; Miclo, Laurent; Roth, Stephane; Spiesser, Estelle; Moille, Daniel; Gaillard, Jean-Luc
 CS Laboratoire des BioSciences de l'Aliment, Faculte des Sciences, UA INRA, 885, Vandoeuvre-les-Nancy, 54500, Fr.
 SO Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept. 10-15, 2000 (2001), Meeting Date 2000, 755-756.
 Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Publisher: Editions EDK, Paris, Fr.
 CODEN: 69EDMK; ISBN: 2-84254-048-4

DT Conference
 LA English
 AB Bovine α S2-casein was subjected to trypic hydrolysis. Generated peptides had angiotensin I-converting enzyme inhibitory activity and μ and δ opioid receptor binding activities.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:833514 HCAPLUS
 DN 138:162404
 TI Angiotensin-I-converting enzyme inhibitory peptides from tryptic hydrolysate of bovine α S2-casein
 AU Tazin, Jerome; Miclo, Laurent; Gaillard, Jean-Luc
 CS Laboratoire des BioSciences de l'Aliment, Faculte des Sciences et Techniques, UC 885 INRA, Universite Henri Poincare Nancy 1, Vandoeuvre-les-Nancy, 54506, Fr.
 SO FEBS Letters (2002), 531(2), 369-374
 CODEN: FEBLAL; ISSN: 0014-5793
 PB Elsevier Science B.V.
 DT Journal
 LA English
 AB Angiotensin-I-converting enzyme (ACE) inhibitory activity of a tryptic digest of bovine α S2-casein (α S2-CN) was extensively investigated. Forty-three peptide peaks were isolated and tested. Seven casokinins (i.e. CN-derived ACE inhibitory peptides) were identified and their IC50 values were determined. Four peptides exhibited an IC50 value lower than 20 μ M. Peptides α S2-CN (f174-181) and α S2-CN (f174-179) had IC50 values of 4 μ M. Surprisingly, deletion of the C-terminal dipeptide of two of these casokinins did not significantly alter their inhibitory activity.

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN
 DN 2002:171931 HCAPLUS
 TI Identification of Sequential IgE-Binding Epitopes on Bovine α S2-Casein in Cow's Milk Allergic Patients
 AU Busse, Paula J.; Jaervinen, Kirsi-Marjut; Vila, Leticia; Beyer, Kirsten; Sampson, Hugh A.
 CS Jaffe Institute for Food Allergy, Division of Allergy and Immunology, Department of Pediatrics, The Mount Sinai School of Medicine, New York, NY, 10029-6574, USA
 SO International Archives of Allergy and Immunology (2002), 129(1), 93-96
 CODEN: IARIN; ISSN: 1018-2438
 PB S. Karger AG
 DT Journal
 LA English
 AB Background: Casinins are the major allergens responsible for

AN	2002152829	HCAPLUS	AN	200231272	HCAPLUS
DN	13719685		DN	136107509	
TI	Molecular genetic characterization of the goat α S2- casein E allele		TI	α - Casein peptide composition for retarding aging of the skin and treating periodontal disease	
AU	Lagonigro, R.; Pietrola, E.; D'Andrea, M.; Veltri, C.; Pilla, F.		IN	Smith, John Arthur	
CS	Dipartimento di Scienze Animali Vegetali e dell' Ambiente, Universita del Molise, Campobasso, Italy		PA	Pepsyn Ltd., UK	
SO	Animal Genetics (2001), 32(6), 391-393		SO	PCT Int. Appl., 27 pp.	
CODEN:	ANGB33; ISSN: 0268-9146		CODEN: PIXXD2		
PB	Blackwell Science Ltd.		DT	Patent	
DT	Journal		LA	English	
LA	English		PAN.CNTL	1	
AB	As2 casein is one of the major protein of ruminants milk, and in goats, four alleles have already been described at the DNA level. DNA was extracted from whole blood of a goat specimen showing a homozygous E pattern to detect the amniotic variant. All 18 exons of the α S2 gene were amplified and sequenced, using primers selected according to the bovine intronic sequence. A mutation was identified at the eighty-third base of the exon 16, where cytosine was replaced by a guanine. In the encoded E protein variant, a proline replaced by an arginine in position 197 of the mature protein. The sequence of the amplified cDNA confirmed that the E allele presented a nucleotide substitution in the eighty-third base of the exon 16.		PATENT NO.	KIND	DATE
RE.CNT	4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD		PI	WO 200202133	20020110
ALL CITATIONS AVAILABLE IN THE RE FORMAT			WO	2001-GB2601	20010613
LI4	ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN		WO	20021017	20010613
AN	2002137476	HCAPLUS	W:	AB, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, NY, PL, PT, RO, RU, SD, SE, SG, SL, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, KE, LS, MW, MZ, SD, SL, SZ, TM, RU, TJ, RW: GH, GM, DE, DK, ES, FI, FR, GB, GR, IT, IU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GW, ML, MR, NS, SN, TD, TG	
DN			CA	2001-2412836	20010613
TI	Three oligopeptide-binding proteins are involved in the oligopeptide transport of <i>Streptococcus thermophilus</i>		CA	20020110	20010613
AU	Garaud, Peggy; Le Bars, Dominique; Besset, Colette; Monnet, Veronique		EP	1317274	20030611
CS	Unité de Biochimie et Structure des Protéines, Institut National de la Recherche Agronomique, Jouy en Josas, 78352, Fr.		EP	A2	20010613
SO	Journal of Biological Chemistry (2002), 277(1), 32-39		JP	2004501976	20010613
CODEN:	JBCH3; ISSN: 0021-9258		JP	T2	20040122
PB	American Society for Biochemistry and Molecular Biology		US	2004014653	20030618
DT	Journal		US	A1	20040122
LA	English		PRAT	GB 2000-161919	20000630
AB	The functions necessary for bacterial growth strongly depend on the features of the bacteria and the components of the growth media. Our objective was to identify the functions essential to the optimum growth of <i>Streptococcus thermophilus</i> in milk. Using random insertion mutagenesis on a <i>S. thermophilus</i> strain chosen for its ability to grow rapidly in milk, we obtained several mutants incapable of rapid growth in milk. We isolated and characterized one of these mutants in which an AmiA1 gene encoding an oligopeptide-binding protein (OBP) was interrupted. This gene was a part of an operon containing all the components of an OBP binding cassette transporter. Three highly homologous amiA genes encoding OBPs work with the same components of the ATP transport system. Their simultaneous inactivation led to a drastic diminution in the growth rate in milk and the absence of growth in chemical defined medium containing peptides as the nitrogen source. We constructed single and multiple neg. mutants for AmiA and cell wall proteinase (PrtS). The only proteinase capable of hydrolyzing casein oligopeptides outside the cell. Growth experiments in chemical defined medium containing peptides indicated that AmiA1, Ami2, and AmiA3 exhibited overlapping substrate specificities, and that the whole system allows the transport of peptides containing from 3 to 23 residues.		WO	2001-GB2501	20010613
RE.CNT	45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD		AB	Provided is use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in alleviating or preventing periodontal disease, wherein the peptide comprises an amino acid sequence present in an α -S2 casein precursor, said sequence comprising 3 or more amino acids and not comprising at its N-terminal amino acid of the full α -S2 casein precursor. The peptide may alternatively be any peptide having an α -S2 casein fragment activity. Further provided is use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in alleviating or preventing an effect of aging in skin, wherein the peptide comprises an amino acid sequence comprising 3 or more amino acids, and not comprising at its N-terminal amino acid of the full α -S2 casein precursor. The peptide may alternatively be any peptide having an α -S2 casein fragment activity.	
LI4	ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN		LI4	ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN	
AN	200029852	HCAPLUS	AN	200029852	HCAPLUS
DN	13219930		DN	13219930	
TI	Casein related amyloid, characterization of a new and unique amyloid protein isolated from bovine corpora amylacea		TI	Casein related amyloid, characterization of a new and unique amyloid protein isolated from bovine corpora amylacea	
AU	Nieuwold, Theodoor A.; Murphy, Charles L.; Hulstamp Koch, Claartje A. M.; Tooten, Peter C. J.; Gruys, Erik		AU	Nieuwold, Theodoor A.; Murphy, Charles L.; Hulstamp Koch, Claartje A. M.; Tooten, Peter C. J.; Gruys, Erik	
CS	Institute for Animal Science and Health (ID-DLO), Lelystad, NL-8200 AB, Neth.		CS	Institute for Animal Science and Health (ID-DLO), Lelystad, NL-8200 AB, Neth.	
SO	Amyloid (1999), 6(4), 244-249		SO	Amyloid (1999), 6(4), 244-249	
PB	CODEN: ALJIE; ISSN: 1350-6129		PB	Parthenon Publishing Group	
DT	Journal		DT	Parthenon Publishing Group	
LA	English		LA	English	
AB	Amyloid bodies can be found in mammary secretory tissue of various		AB	Amyloid bodies can be found in mammary secretory tissue of various	

species. These corpora amylacea (CA) have a lamellated structure, contain amyloid fibrils and are predominantly located in the alveolar lumina. The nature of the amyloid was not known, but CA were suggested to originate either from milk casein or mammary alveolar epithelial keratin. In the present report, bovine CA were analyzed histochem. Furthermore, CA were isolated, analyzed and the amyloid was purified and characterized by amino acid sequencing. CA amyloid appeared to be potassium permanganate sensitive and tryptophan pos., and in this respect different from most other amyloid types except for α 1 and β -2 microglobulin amyloid. Gel filtration of purified amyloid fibrils showed a MW peak and a major 4 kDa peak. N-terminal amino acid sequencing showed the amyloid to consist of tryptic-like peptides with an unusually high content of amino acids with bulky side chains. The amyloid protein was identified as derived from α -S2-casein. The fragments are of varying length (32, 33 and 45 amino acids), but all start at position 81 of α -S2-casein. We have identified a new and unique amyloid protein, and we propose to designate it as according to the guidelines for amyloid nomenclature.

RE: CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN
DN 1995:71228 HCAPLUS
DN 122:284799
TI Biochemical and genetic analysis of variant C of caprine α s2-casein (Capra hircus)
AU Bouniol, C.; Brignon, G.; Mahe, M. F.; Printz, C.
CS Unit de developpement concertee INSERM U-310-INRA Station 806, Institut de Biologie Physico-chimique, Paris, 75005, Fr.
SO Animal Genetics (1994), 25(3), 173-7
CODEN: ANGEE3; ISSN: 0268-9146
DT Journal
LA English
AB Two alleles, A and B, were previously described at the goat α s2-casein locus. Isoelec. focusing allowed the us to subdivide the former one in two new alleles, called A and C. Although α s2-casein C cannot actually be distinguished from its A counterpart by search or PAGE, it differs from the previous allele by a single substitution Iys (A)/Ile (C) at position 167, which was confirmed at the nucleotide level. The frequencys of the three α s2-casein alleles A, B and C were estimated to be 0.85, 0.04 and 0.11 in the French dairy breeds "Alpine" and "Saanen".

ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN

DN 1994:210960 HCAPLUS
TI Characterization of goat allelic α s2-caseins A and B: Further evidence of the phosphorylation code of caseins
AU Bouniol, Christine; Brignon, Ghislaine; Mahe, Marie-Francoise; Printz, Christiane
CS Lab. Genet. Biochim., INRA, Jouy-en-Josas, F-28352, Fr.
SO Protein Sequences & Data Analysis (1993), 5(5), 213-8
CODEN: PSDAB6; ISSN: 0931-9506
DT Journal
LA English
AB As in other European goat breeds, in the French 'Alpine' and 'Saanen' goat races α s2-casein exists as two allelic forms, A and B, identified by gel electrophoresis. Anal. of elution profiles of enzymic digests of purified α s2-caseins A and B fractions and sequencing of some relevant peptides allowed the chemical characterization of both genetic variants, and these are in good agreement with the observed electrophoretic mobilities. α s2-casein B differs from its predominant A counterpart (allelic frequency approx. 0.85) by an amino acid substitution Ser-Ala-Lys (B)/SerP62-Ala-Glu64 (A), which provides indirect

evidence of the phosphorylation code of caseins. The lack of a phosphate group on Ser62 in variant α s2-casein B can be readily explained by the Lys/Glu replacement which affects the Glu determinant in the tripeptide phosphorylation recognition site.

ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1993:228588 HCAPLUS
DN 11:228588
TI Sequence of the goat α s2-casein-encoding cDNA
AU Bouniol, Christine
CS Lab. Genet. Biochim., Inst. Natl. Rech. Agron., Jouy-en-Josas, 78350, Fr.
SO Gene (1993), 125(2), 235-6
CODEN: GENED6; ISSN: 0378-1119
DT Journal
LA English
AB The complete nucleotide sequence of a caprine α s2-casein-encoding cDNA and the deduced 223-amino-acid sequence of pre- α s2-casein were determined

ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1992:167497 HCAPLUS
DN 116:167497
TI Multiple mRNA species code for two non-allelic forms of ovine α s2-casein
AU Bouniol, Monique; Hue, Dominique; Bouniol, Christine; Mercier, Jean Claude; Gaye, Pierre
CS Unité Endocrinol. Mol. Inst. Natl. Rech. Agron., Jouy-en-Josas, Fr.
SO European Journal of Biochemistry (1991), 201(3), 633-41
CODEN: EUBCAI; ISSN: 0014-2956
DT Journal
LA English
AB The two-allelic forms of α s2-casein, occurring in ovine milk, differ by an internal deletion of nine amino acid residues, including both cysteine residues at positions 34 and 42 in the mature chain. Sequencing of several α s2-casein cDNAs, isolated from the mammary cDNA library of a single lactating ewe, showed three new types which differed from that previously studied. In addition to the expected deletion of codons 34 to 42, affecting 30-40% of mRNA, another structural difference involving an internal stretch of 44 nucleotides in the 5'-untranslated region, was found. S1-nuclease protection assays confirmed the existence of several types of the relevant mRNA and sequencing of in-vitro-amplified genomic DNA demonstrated the presence of the 44-nucleotide stretch in the α s2-casein transcript, thus ruling out the possibility of a cloning artifact. The different α s2-casein mRNA, four containing deletions and two containing nucleotide substitutions for a given ewe, can be readily explained by partial exon skipping and allelic differences, resp. This assumption is well supported by the following observations: 5' and 3' ends of both deleted DNA fragments are similar to those of exons; sequences neighboring the 44-nucleotide stretch of the genomic DNA perfectly match consensus sequences described for 3' and 5' ends of introns; the rather simple patterns observed on Southern blots of different enzymic digests of genomic DNA strongly suggest the occurrence of only 1 copy of the α s2-casein gene/haploid genome. During the course of evolution, the α s2-casein encoding gene has undergone many mutations and some of them might have occurred in regions corresponding to consensus splicing regions of the pre-mRNA. Thus, complete skipping of some exons might be responsible for the shorter sizes of rat and mouse α s2-casein mRNA. If so, the overall organization of the α s2-casein gene in the different species might be more similar than expected from structural comparisons of the cognate mRNA or caseins.

ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1992:167497 HCAPLUS
DN 116:167497
TI Multiple mRNA species code for two non-allelic forms of ovine α s2-casein
AU Bouniol, Monique; Hue, Dominique; Bouniol, Christine; Mercier, Jean Claude; Gaye, Pierre
CS Unité Endocrinol. Mol. Inst. Natl. Rech. Agron., Jouy-en-Josas, Fr.
SO European Journal of Biochemistry (1991), 201(3), 633-41
CODEN: EUBCAI; ISSN: 0014-2956
DT Journal
LA English
AB The two-allelic forms of α s2-casein, occurring in ovine milk, differ by an internal deletion of nine amino acid residues, including both cysteine residues at positions 34 and 42 in the mature chain. Sequencing of several α s2-casein cDNAs, isolated from the mammary cDNA library of a single lactating ewe, showed three new types which differed from that previously studied. In addition to the expected deletion of codons 34 to 42, affecting 30-40% of mRNA, another structural difference involving an internal stretch of 44 nucleotides in the 5'-untranslated region, was found. S1-nuclease protection assays confirmed the existence of several types of the relevant mRNA and sequencing of in-vitro-amplified genomic DNA demonstrated the presence of the 44-nucleotide stretch in the α s2-casein transcript, thus ruling out the possibility of a cloning artifact. The different α s2-casein mRNA, four containing deletions and two containing nucleotide substitutions for a given ewe, can be readily explained by partial exon skipping and allelic differences, resp. This assumption is well supported by the following observations: 5' and 3' ends of both deleted DNA fragments are similar to those of exons; sequences neighboring the 44-nucleotide stretch of the genomic DNA perfectly match consensus sequences described for 3' and 5' ends of introns; the rather simple patterns observed on Southern blots of different enzymic digests of genomic DNA strongly suggest the occurrence of only 1 copy of the α s2-casein gene/haploid genome. During the course of evolution, the α s2-casein encoding gene has undergone many mutations and some of them might have occurred in regions corresponding to consensus splicing regions of the pre-mRNA. Thus, complete skipping of some exons might be responsible for the shorter sizes of rat and mouse α s2-casein mRNA. If so, the overall organization of the α s2-casein gene in the different species might be more similar than expected from structural comparisons of the cognate mRNA or caseins.

AN 1986:46554 HCAPLUS
DN 104:6554
TI Complete sequence of ovine α s2- casein messenger RNA
AU Boisnard, Monique; Perrissant, Guy
CS Lab. Physiol. Lactation, INRA, Jouy-en-Josas, 78350, Fr.
SO Biochimie (1985), 67 (9), 1043-51
CODEN: BICMB; ISSN: 0300-9084
DT Journal
LA English
AB The primary structure of mRNA coding for ovine α s2 casein was determined by chemical sequencing of 3 cDNA clones and of the primer extension products of the longest one. The mRNA was 1024 nucleotides long, excluding the poly(A) tail. The lengths of the 5'-noncoding, coding and 3'-noncoding regions were 53, 669 and 302 nucleotides, resp. A comparison of the nucleotide sequences of ovine α s2- casein and guinea-pig casein A mRNAs revealed an extensive homol. in the 5'- and 3'-noncoding regions. The deduced amino acid sequence of ovine α s2 casein was compared with its bovine and guinea pig counterparts. An heterogeneity was evidenced in the mRNA population of the α s2 casein.

L14 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2006 ACS on STN
DN 1977:41534 HCAPLUS
DN 87:17534 HCAPLUS
TI Complete amino acid sequence of bovine α s2- casein
AU Brigthon, Ghislaine; Ribadeau Dumas, Bruno; Mercier, Jean Claude;
Pelissier, Jean Pierre; Bas, B. C.
CS Lab. Rech. Proteines, Inst. Natl. Rech. Agron., Jouy-en-Josas, Fr.
SO FEBS Letters (1977), 76 (2), 274-9
CODEN: FEBBLA; ISSN: 0014-5793
DT Journal
LA English
AB The complete primary amino acid sequence of bovine α s2- casein was determined by standard methods. In addition, the possible sites of phosphorylation on this protein were localized. This protein contains 207 amino acid residues, including 2 cysteines, and 10-13 phosphate groups and has a calculated mol. weight of 25,150-15,390 daltons.

=> d his

(FILE 'HOME' ENTERED AT 14:31:21 ON 08 AUG 2006)

FILE 'REGISTRY' ENTERED AT 14:31:44 ON 08 AUG 2006
L1 1 S NNAINPSK/SQSP
L2 4 S NNAINPSK/SQSP
L3 1 S FALIQV/SQSP
L4 65 S FALPQV/SQSP
L5 1 S FQYQYQ/SQSP
L6 30 S FQYQYQ/SQSP

FILE 'HCAPLUS' ENTERED AT 14:34:35 ON 08 AUG 2006
L7 3 S L1
L8 6 S L2
L9 2 S L3
L10 66 S L4
L11 3 S L5
L12 16 S L6
L13 17 S L4 AND CASEIN
L14 16 S L6 AND CASEIN